Possible Trump FDA Commish Candidate Favors (Much) Lighter Touch
Executive Summary
The Trump transition team is considering Jim O'Neill, a Silicon Valley investment manager, to head US FDA, according to news reports. Previous comments from O'Neill – who has some HHS experience – suggest, he favors substantially reducing FDA's role in assessing product effectiveness. While some experts are highly skeptical about O'Neill, others suggest he could champion much-needed change at the agency.
You may also be interested in...
FDA Confirmation Watch: Gottlieb Likely To Face Questions About Approval Standards, Ties To Industry
Top HELP Committee Democrat Patty Murray tweeted concerns about Gottlieb's positions on the "gold standard" of FDA approval; Pubic Citizen's Michael Carome ultimately thinks Gottlieb will be approved.
Gottlieb At FDA: Industry Will Look For User-Fee Deal Support, Restrained Regulations
After months of waiting on whether President Trump would pick a conventional FDA commissioner candidate or go off the beaten path, the White House appears to be taking the former approach. Trump is expected to nominate Scott Gottlieb, a George W. Bush administration FDA alum, physician and long-time conservative voice on health policy. Gottlieb will favor reduced regulatory burdens, and industry hopes he will help push forward a device user-fee reauthorization agreement.
Trump Meets With Two US FDA Commissioner Candidates; Third Still Lurking
O'Neill and Srinivasan head to Trump Tower, but Gottlieb has not been eliminated.